Quartiles of serum GPx3 activity (units/L)Continuous (per 100 units/L)
<589589-655655-715≥715
Cases/controls (n)70/12165/12548/12365/1230.29
0.570.070.680.93
Crude OR* (95% CI)1.000.89 (0.58, 1.35)0.67 (0.43, 1.04)0.92 (0.60, 1.40)(0.81, 1.07)
0.360.050.460.17
Adjusted OR (95% CI)1.000.82 (0.53, 1.26)0.63 (0.39, 0.99)0.85 (0.55, 1.31)0.91 (0.79, 1.04)
Excluding cases diagnosed during 1st year of follow-up (and matched controls)
Cases/controls (n)68/11663/11644/11960/155
Adjusted OR (95% CI)1.000.84 (0.54, 1.31)0.59 (0.36, 0.94)0.83 (0.53, 1.30)0.88 (0.76, 1.02)
High-grade prostate cancer
Cases/controls (n)27/4526/4821/4418/45
Adjusted OR (95% CI)1.000.86 (0.43, 1.73)0.82 (0.41, 1.65)0.68 (0.33, 1.40)0.85 (0.67, 1.09)
Low-grade prostate cancer
Cases/controls (n)39/6632/6523/6636/61
Adjusted OR (95% CI)1.000.74 (0.40, 1.36)0.50 (0.25, 0.99)0.80 (0.42, 1.52)0.90 (0.74, 1.10)
  • *Crude OR from conditional logistic regression stratified by matching factors (age group and time of recruitment).

  • Adjusted OR additionally adjusted for family history of prostate cancer, participation in PSA testing, smoking status, and vigorous physical activity.